Dimesna free acid

Synonyms: BNP-7787 free acid
Dimesna (BNP-7787) free acid 是 Mesna (MS-U04938) 的二硫化物形式,作为一种铂类相关毒性防护剂,它可转化为 Mesna 进而使有毒的铂类物质失活,且不干扰铂类化合物的抗肿瘤活性,不影响 Cisplatin (MS-E94993) 或 Carboplatin (MS-L77931) 的抗增殖作用,可对抗 Cisplatin 诱导的肾毒性,对肾脏具有选择性保护作用,可用于卵巢癌、顺铂诱导的肾毒性相关研究。
产品编号: MS-I16842 CAS No.: 45127-11-5 分子式: C4H10O6S4 分子量: 282.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Dimesna (BNP-7787) free acid 是 Mesna (MS-U04938) 的二硫化物形式,作为一种铂类相关毒性防护剂,它可转化为 Mesna 进而使有毒的铂类物质失活,且不干扰铂类化合物的抗肿瘤活性,不影响 Cisplatin (MS-E94993) 或 Carboplatin (MS-L77931) 的抗增殖作用,可对抗 Cisplatin 诱导的肾毒性,对肾脏具有选择性保护作用,可用于卵巢癌、顺铂诱导的肾毒性相关研究。

生物实验数据

生物活性 Dimesna (BNP-7787) free acid, the disulfide form of Mesna (MS-U04938), is a protective agent against platinum-related toxicity that is converted to Mesna, which in turn inactivates toxic platinum species, without interfering with the antitumor activity of platinum compounds, without affecting the antiproliferative effects of Cisplatin (MS-E94993) or Carboplatin (MS-L77931), and can counteract Cisplatin-induced nephrotoxicity, exhibiting selective renal protection, and is applicable for research related to ovarian cancer and cisplatin-induced nephrotoxicity.
体外研究
(In Vitro)

Dimesna (0-5.0 mmol/L; 1-24 h) free acid 单独使用时对 LLC-PK1 细胞的总蛋白、胸苷掺入或尿苷掺入无影响,无法保护 LLC-PK1 细胞免受异环磷酰胺、环磷酰胺、4-过氧羟基异环磷酰胺、氯乙醛或丙烯醛诱导的毒性。
Dimesna (≥2.0×103; 96 h) free acid 不会降低顺铂或卡铂对 A2780 或 OVCAR-3 卵巢癌细胞的抗增殖作用,仅在暴露时长为 96 h 且浓度 ≥2.0×103 μM 时才会抑制这些细胞的生长。

Cell Viability Assay

Cell Line: LLC-PK1 renal tubular cells
Concentration: 0-5.0 mmol/l (alone; co-incubated with ifosfamide/cyclophosphamide/4-OOH-ifosfamide/chloracetaldehyde/acrolein); 1.0-5.0 mmol/l (co-incubated with 4-OOH-cyclophosphamide)
Incubation Time: 1-24 h (alone); 1 h pre-incubation + 23 h co-incubation (with cytostatic metabolites)
Result: Had no significant effect on total protein, thymidine incorporation, or uridine incorporation at all tested concentrations and times when used alone.
Moderately stimulated thymidine incorporation, but had no significant effect on total protein or uridine incorporation when co-incubated with 150 μmol/l ifosfamide.
Had no significant effect on total protein, thymidine incorporation, or uridine incorporation when co-incubated with 150 μmol/l cyclophosphamide.
Further reduced total protein and thymidine incorporation at 1.0, 3.0, 5.0 mmol/l, and further reduced uridine incorporation at 3.0, 5.0 mmol/l (P < 0.05) when co-incubated with 75 μmol/l 4-OOH-cyclophosphamide.
Failed to protect cells from toxicity induced by 150 μmol/l 4-OOH-ifosfamide, with total protein, thymidine incorporation, and uridine incorporation remaining strongly reduced.
Failed to protect cells from toxicity induced by 75 μmol/l chloracetaldehyde, with no statistically significant difference in total protein, thymidine incorporation, or uridine incorporation compared to chloracetaldehyde alone.
Failed to protect cells from toxicity induced by 100 μmol/l acrolein, with total protein, thymidine incorporation, and uridine incorporation remaining severely reduced.
体内研究
(In Vivo)

Dimesna (静脉注射,1000 mg/kg) free acid 不会干扰顺铂或卡铂在 OVCAR-3 卵巢癌异种移植物中的抗肿瘤活性;与 60 mg/kg 卡铂联合给予时,其肿瘤生长抑制作用显著强于单独使用卡铂。
Dimesna (BNP-7787)(1000 mg/kg;静脉推注) free acid 给予荷瘤 Fischer 大鼠后,会使其代谢产物美司钠在肾脏中优先蓄积,肾脏中美司钠的 AUC0-t 较血浆中美司钠的 AUC0-t 高 4.5 倍;同时与直接给予美司钠相比,其血浆和肿瘤组织中的美司钠水平维持在较低水平。

Animal Model: Hsd: athymic nude-nu (female, 8-10 weeks old)
Dosage: 1000 mg/kg (pre-cisplatin 5 mg/kg); 1000 mg/kg (pre-cisplatin 8 mg/kg); 1000 mg/kg (with carboplatin 60 mg/kg); 1000 mg/kg (with carboplatin 90 mg/kg); 1000 mg/kg (monotherapy)
Administration: i.v.; weekly ×2 (pre-cisplatin 5 mg/kg); i.v.; every 2 weeks ×2 (pre-cisplatin 8 mg/kg); i.v.; twice per treatment cycle, weekly ×2 (with carboplatin 60 mg/kg); i.v.; twice per treatment cycle, weekly ×2 (with carboplatin 90 mg/kg); i.v.; weekly ×2 (monotherapy)
Result: Exhibited mean maximum weight loss of 6.6±6.1%, no toxic deaths, specific growth delay of 3.48, and mean relative tumour volume of 2.55±0.42 on day 31 when given 5 minutes before 5 mg/kg cisplatin, with no significant difference in tumour growth inhibition compared to cisplatin alone.
Exhibited mean maximum weight loss of 24.8±9.2%, no toxic deaths, specific growth delay of 6.34, and mean relative tumour volume of 0.39±0.08 on day 31 when given 5 minutes before 8 mg/kg cisplatin, with no significant difference in tumour growth inhibition compared to amifostine-pretreated cisplatin.
Exhibited mean maximum weight loss of 9.9±11.9%, no toxic deaths, specific growth delay of 4.72, and mean relative tumour volume of 0.50±0.14 on day 31 when given with 60 mg/kg carboplatin, which was significantly smaller than carboplatin alone (P<0.01).
Exhibited mean maximum weight loss of 11.4±3.1%, 2 out of 6 mice died from toxicity, specific growth delay of 8.44, and mean relative tumour volume of 0.17±0.03 on day 31 when given with 90 mg/kg carboplatin.
Exhibited mean maximum weight loss of 0.0±3.2%, no toxic deaths, specific growth delay of 0.22, and mean relative tumour volume of 29.28±4.38 on day 31 as monotherapy, with no tumour growth inhibition observed.

化学信息

分子量 282.38
分子式 C4H10O6S4
CAS No. 45127-11-5
别名 BNP-7787 free acid

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础